BackTurning Point Therapeutics Overview

Turning Point Therapeutics Total Current Liabilities

Turning Point Therapeutics's total current liabilities is $49M.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$49.42M
54.96% YoYΔ $17.53M vs prior year quarter

Peer average

Loading

Turning Point Therapeutics Total Current Liabilities History

Loading

Turning Point Therapeutics vs. peers: Total Current Liabilities Comparison

Loading

Turning Point Therapeutics Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Turning Point Therapeutics (TPTX) FAQ

As of the most recent data (June 2022), TPTX shows a total current liabilities of $49M. That compares with $32M in the prior-year period — up 55.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, TPTX's total current liabilities is now $49M (was $32M) — a 55.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Turning Point Therapeutics is outperforming or lagging.

Tracking TPTX's total current liabilities over time shows whether Turning Point Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $49M That compares with $32M in the prior-year period — up 55.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total current liabilities page, Stockcircle has Turning Point Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total current liabilities (currently $49M) with ownership activity and broader fundamentals.

Turning Point Therapeutics's total current liabilities is $49M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.